首页> 外文期刊>Clinical Pharmacology and Therapeutics >Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration
【24h】

Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration

机译:儿科药物开发中的浓缩策略:提交给美国食品和药物管理局的试验分析

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical trial enrichment involves prospectively incorporating trial design elements that increase the probability of detecting a treatment effect. The use of enrichment strategies in pediatric drug development has not been systematically assessed. We analyzed the use of enrichment strategies in pediatric trials submitted to the US Food and Drug Administration from 2012-2016. In all, 112 efficacy studies associated with 76 drug development programs were assessed and their overall success rates were 78% and 75%, respectively. Eighty-eight trials (76.8%) employed at least one enrichment strategy; of these, 66.3% employed multiple enrichment strategies. The highest trial success rates were achieved when all three enrichment strategies (practical, predictive, and prognostic) were used together within a single trial (87.5%), while the lowest success rate was observed when no enrichment strategy was used (65.4%). The use of enrichment strategies in pediatric trials was found to be associated with trial and program success in our analysis.
机译:临床试验富集涉及前瞻性地掺入试验设计元素,从而提高检测治疗效果的可能性。尚未系统地评估使用浓缩策略在儿科药物开发中。我们分析了2012 - 2016年从提交给美国食品和药物管理局提交的儿科试验中的富集策略。总之,评估了与76种药物发展方案相关的112项疗效研究,其总体成功率分别为78%和75%。八十八项试验(76.8%)雇用至少一个浓缩策略;其中,66.3%采用多重浓缩策略。在单一试验中使用三种浓缩策略(实际,预测性和预测性)(87.5%)(87.5%)时,达到了最高的试验成功率,而使用富集策略(65.4%),则观察到最低成功率。发现在我们的分析中发现了儿科试验中的富集策略与审判和计划成功有关。

著录项

  • 来源
  • 作者单位

    US FDA Off Clin Pharmacol Ctr Drug Evaluat &

    Res Silver Spring MD 20993 USA;

    US FDA Off Clin Pharmacol Ctr Drug Evaluat &

    Res Silver Spring MD 20993 USA;

    Univ Michigan Coll Pharm 428 Church St Ann Arbor MI 48109 USA;

    US FDA Off Clin Pharmacol Ctr Drug Evaluat &

    Res Silver Spring MD 20993 USA;

    US FDA Off Clin Pharmacol Ctr Drug Evaluat &

    Res Silver Spring MD 20993 USA;

    US FDA Off Clin Pharmacol Ctr Drug Evaluat &

    Res Silver Spring MD 20993 USA;

    US FDA Off New Drugs Ctr Drug Evaluat &

    Res Silver Spring MD USA;

    US FDA Off Pediat Therapeut Commissioners Off Silver Spring MD USA;

    US FDA Off Clin Pharmacol Ctr Drug Evaluat &

    Res Silver Spring MD 20993 USA;

    US FDA Off Clin Pharmacol Ctr Drug Evaluat &

    Res Silver Spring MD 20993 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号